Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haploidentical NK Cells in High-Risk AML
NCT02229266Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Sep 2015
- Primary completion
- Apr 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 2 trial of haploidentical natural killer cells in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Started Sep 2015; status: terminated.
02
Drugs
haploidentical natural killer cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02229266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02229266.